The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Lashch N.Y.

Pirogov Russian National Research Medical University (Pirogov University)

Ashikhmina A.A.

Pirogov Russian National Research Medical University (Pirogov University)

Kislaya M.I.

Pirogov Russian National Research Medical University (Pirogov University)

Filatova L.A.

Pirogov Russian National Research Medical University (Pirogov University)

Hormonal contraception methods and multiple sclerosis

Authors:

Lashch N.Y., Ashikhmina A.A., Kislaya M.I., Filatova L.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(1): 24‑30

DOI: 10.17116/jnevro202512501124

Views: 616

Downloaded: 4

Buy for 300₽
Contact the author
Table of contents

HORMONAL CONTRACEPTION METHODS AND MULTIPLE SCLEROSIS
HORMONAL CONTRACEPTION METHODS AND MULTIPLE SCLEROSIS

To cite this article:

Lashch NY, Ashikhmina AA, Kislaya MI, Filatova LA. Hormonal contraception methods and multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(1):24‑30. (In Russ.)
https://doi.org/10.17116/jnevro202512501124

 
Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Long-term effi­cacy and safety of divo­zilimab during 2-year treatment of multiple scle­rosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):86-96
A case of COVID-associated ence­phalopathy in a patient with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):159-163
A role of cere­brovascular diseases in the progression of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):53-57
Hemo­rrhagic stroke during pregnancy as a result of rupture of cave­rnous malformation. Clinical case. Russian Journal of Human Reproduction. 2024;(2):90-95
Opti­cal cohe­rence tomo­graphy angiography in the diagnosis of multiple scle­rosis. Russian Annals of Ophthalmology. 2024;(2):63-70
Pecu­liarities of local mRNA gene expression of pro- and anti-inflammatory cyto­kines in term pregnancy. Russian Bulletin of Obstetrician-Gynecologist. 2024;(3):6-13
The problem of diabetes mellitus in obstetrics. Russian Bulletin of Obstetrician-Gynecologist. 2024;(3):25-29
Rela­tionship between pregnancy and the risk of mali­gnant neoplasms of the female reproductive system. Russian Bulletin of Obstetrician-Gynecologist. 2024;(3):48-54
Asse­ssment of the effe­ctiveness of compression therapy in pregnant women with geni­tal vari­cose veins. Russian Bulletin of Obstetrician-Gynecologist. 2024;(3):60-65
Expe­rience of combined treatment of patients with infe­rtility operated for exte­rnal geni­tal endo­metriosis. Russian Bulletin of Obstetrician-Gynecologist. 2024;(3):77-81

Multiple sclerosis (MS) is a chronic autoimmune demyelinating disease that is diagnosed in women twice as often as in men, especially in groups of family cases and at the age of up to 35 years. Among patients diagnosed with MS, there are many young and middle-aged women who are planning a pregnancy in the future and want to protect themselves from unwanted pregnancy at the present time. Also, for patients with MS, the importance of reducing the frequency of abortions is obvious. The question arises — what drugs are safe, convenient and effective for this group of patients. Moreover, one of the modern hypotheses of treatment in relation to reducing relapses and progression of MS is the use of estrogen. Therefore, the strategy of choice may be the use of estrogen-containing oral contraceptives as means that provide effective protection against pregnancy and at the same time, possibly, affect the course of the underlying disease in a positive way.

Keywords:

multiple sclerosis
contraceptive methods
young women
pregnancy
combined oral contraceptives
estrogen

Authors:

Lashch N.Y.

Pirogov Russian National Research Medical University (Pirogov University)

Ashikhmina A.A.

Pirogov Russian National Research Medical University (Pirogov University)

Kislaya M.I.

Pirogov Russian National Research Medical University (Pirogov University)

Filatova L.A.

Pirogov Russian National Research Medical University (Pirogov University)

Received:

16.09.2024

Accepted:

30.09.2024

List of references:

  1. Gusev EI, Boyko AN. Rasseyannyy skleroz. Nauchno-prakticheskoe rukovodstvo v dvukh tomakh. T. 1. M.: ROOI «Zdorovʹe cheloveka». 2020;608: il. (In Russ.).
  2. Runmarker B, Andersen O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain. 1995;118 (1):253-261.  https://doi.org/10.1093/brain/118.1.253
  3. Devonshire V, Duquette P, Dwosh E, et al. The immune system and hormones: review and relevance to pregnancy and contraception in women with MS. International MS Journal. 2003;10(2):44-50. 
  4. Landi D, Ragonese P, Prosperini L, et al. Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. 2018;89(12):1272-1278. https://doi.org/10.1136/jnnp-2018-318468
  5. Houtchens MK, Zapata LB, Curtis KM, et al. Contraception for women with multiple sclerosis: Guidance for healthcare providers. Multiple Sclerosis. 2017;23(6):757-764.  https://doi.org/10.1177/1352458517701314
  6. Sondheimer SJ. Oral contraceptives: mechanism of action, dosing, safety, and efficacy. Cutis. 2008;81(1):19-22. 
  7. Tomassini V, Pozzilli C. Sex hormones: a role in the control of multiple sclerosis? Expert opinion on pharmacotherapy. 2006;7(7):857-868.  https://doi.org/10.1517/14656566.7.7.857
  8. Vessey MP, Lawless M. The Oxford- Family Planning Association contraceptive study. Clin Obstet Gynaecol. 1984;11:743-757. 
  9. Hannaford PC, Selveraj S, Elliott AM, et al. Cancer risk among users of oral contraceptives: cohort data from 53. J Turk Ger Gynecol Assoc. 2015;16:49-53. 
  10. Turkyilmaz E, Yildirim M, Avzar AF. Multiple sclerosis; a disease of reproductive-aged women and the dilemma involving contraceptive methods. J Turk Ger Gynecol Assoc. 2015;16(1):49-53.  https://doi.org/10.5152/jtgga.2015.15186
  11. Gava G, Bartolomei I, Costantino A, et al. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis. Fertility and sterility. 2014;102(1):116-122.  https://doi.org/10.1016/j.fertnstert.2014.03.054
  12. Otero-Romero S, Carbonell-Mirabent P, Midaglia L, et al. Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis. Mult Scler. 2022;28(6):950-957.  https://doi.org/10.1177/13524585211053001
  13. Zhang Z, Yang R, Cai W, et al. Treatment with progesterone after focal cerebral ischemia suppresses proliferation of progenitor cells but enhances survival of newborn neurons in adult male mice. Neuropharmacology. 2010;58(6):930-939. 
  14. Tiwari-Woodruff S, Morales LB, Lee R, et al. Differential neuroprotective and antiinflammatory effects of estrogen receptor (ER)alpha and ERbeta ligand treatment. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(37):14813-14818. https://doi.org/10.1073/pnas.0703783104
  15. Spence RD, Voskuhl RR. Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration. Frontiers in Neuroendocrinology. 2012;33(1):105-115.  https://doi.org/10.1016/j.yfrne.2011.12.001
  16. Robinson AP, Harp CT, Noronha A, et al. The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handbook of clinical neurology. 2014;122:173-189.  https://doi.org/10.1016/B978-0-444-52001-2.00008-X
  17. Lélu K, Delpy L, Robert V, et al. Endogenous estrogens, through estrogen receptor α, constrain autoimmune inflammation in female mice by limiting CD4+ T-cell homing into the CNS. European journal of immunology. 2010;40(12):3489-3498. https://doi.org/10.1002/eji.201040678
  18. Kim RY, Mangu D, Hoffman AS, et al. Oestrogen receptor β ligand acts on CD11c+ cells to mediate protection in experimental autoimmune encephalomyelitis. Brain. 2018;141(1):1321-1347. https://doi.org/10.1093/brain/awx315
  19. Ziehn MO, Avedisian AA, Dervin SM, et al. Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease. Lab Invest. 2012;92(8):1234-1245. https://doi.org/10.1038/labinvest.2012.76
  20. D’Agostino P, Milano S, Barbera C, et al. Sex hormones modulate inflammatory mediators produced by macrophages. Annals of the New York Academy of Sciences. 1999;876:426-429.  https://doi.org/10.1111/j.1749-6632.1999.tb07667.x
  21. Itoh N, Kim R, Peng M, et al. Bedside to bench to bedside research: Estrogen receptor beta ligand as a candidate neuroprotective treatment for multiple sclerosis. J Neuroimmunol. 2017;304:63-71.  https://doi.org/10.1016/j.jneuroim.2016.09.017
  22. Alonso A, Jick SS, Olek MJ, et al. Recent use of oral contraceptives and the risk of multiple sclerosis. Archives of neurology. 2005;62(9):1362-1365. https://doi.org/10.1001/archneur.62.9.1362
  23. Villard-Mackintosh L, Vessey MP. Oral contraceptives and reproductive factors in multiple sclerosis incidence. Contraception. 1993;47(2):161-168.  https://doi.org/10.1016/0010-7824(93)90088-o
  24. Collongues N, Patte-Mensah C, De Seze J, et al. Testosterone and estrogen in multiple sclerosis: from pathophysiology to therapeutics. Expert review of neurotherapeutics. 2018;18(6):515-522.  https://doi.org/10.1080/14737175.2018.1481390
  25. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352(9139):1498-504. Erratum in: Lancet 1999;353(9153):678.  https://doi.org/10.1016/S0140-6736(98)03334-0
  26. Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology. 1999;53(8):1622-1627. https://doi.org/10.1212/wnl.53.8.1622
  27. David OJ, Ocwieja M, Meiser K, et al. Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results. Int J Clin Pharmacol Ther. 2012;50(8):540-544.  https://doi.org/10.5414/CP201675
  28. Zhu B, Nestorov I, Zhao G, et al. Evaluation of Potential Drug-Drug Interaction Between Delayed-Release Dimethyl Fumarate and a Commonly Used Oral Contraceptive (Norgestimate/Ethinyl Estradiol) in Healthy Women. Clin Pharmacol Drug Dev. 2017;6(6):604-613.  https://doi.org/10.1002/cpdd.377
  29. van Hylckama Vlieg A, Middeldorp S. Hormone therapies and venous thromboembolism: where are we now? Journal of thrombosis and haemostasis: JTH. 2011;9(2):257-266.  https://doi.org/10.1111/j.1538-7836.2010.04148.x
  30. Peeters PJ, Bazelier MT, Uitdehaag BM, et al. The risk of venous thromboembolism in patients with multiple sclerosis: the Clinical Practice Research Datalink. Journal of thrombosis and haemostasis: JTH. 2014;12(4):444-451.  https://doi.org/10.1111/jth.12523
  31. Zapata LB, Oduyebo T, Whiteman MK, et al. Contraceptive use among women with multiple sclerosis: a systematic review. Contraception. 2016;94(6):612-620.  https://doi.org/10.1016/j.contraception.2016.07.013
  32. Демехова М.Ю. Гормональная контрацепция и венозные тромбоэмболические осложнения у женщин. Русский медицинский журнал. Мать и дитя. 2017;(12):884-888. 
  33. Demekhova MYu. Hormonal contraception and venous thromboembolic complications in women. Russkii meditsinskii zhurnal. Mat’ i ditya. 2017;(12):884-888. (In Russ.).
  34. Sena A, Macedo A, Ferret-Sena V, et al. Serum Lipoprotein Profile Is Associated With Protective Effects of Oral Contraceptive Use on Multiple Sclerosis Severity: A Cross-Sectional Study. Front Neurol. 2019;10:60.  https://doi.org/10.3389/fneur.2019.00060
  35. Ferret-Sena V, Ramos K, Cascais MJ, et al. Oral Contraceptives Interact with Adiposity-Associated Markers in Patients with Multiple Sclerosis. J Clin Med. 2024;13(2):464.  https://doi.org/10.3390/jcm13020464
  36. Correale J, Marrodan M. Multiple Sclerosis and Obesity: The Role of Adipokines. Front Immunol. 2022;13:1038393. https://doi.org/10.3389/fimmu.2022.1038393
  37. Loonstra FC, Falize KF, de Ruiter LRJ, et al. Adipokines in Multiple Sclerosis Patients Are Related to Clinical and Radiological Measures. J Neurol. 2023;270(4):2018-2030. https://doi.org/10.1007/s00415-022-11519-8
  38. Fallah S, Sanjary Pour M, Rabbani Chadegani A, et al. Adiponectin, Leptin and Lipid Profiles Evaluation in Oral Contraceptive Pill Consumers. Arch Gynecol Obstet. 2012;285:1747-1752. https://doi.org/10.1007/s00404-011-2192-3
  39. Curtis KM, Tepper NK, Jatlaouni TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep. 2016;65(No. RR-3):1-104.  https://doi.org/10.15585/mmwr.rr6503a1
  40. Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(No. RR-4):1-126.  https://doi.org/10.15585/mmwr.rr7304a1
  41. Hsu S, Bove R. Hormonal Therapies in Multiple Sclerosis: a Review of Clinical Data. Curr Neurol Neurosci Rep. 2024;24(1):1-15.  https://doi.org/10.1007/s11910-023-01326-7

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.